Clinical Trials

Neoplasm Metastasis, Cholangiocarcinoma

NCT06728410 2026-05-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

38 enrolled

Cholangiocarcinoma

NCT06906562 2026-02-17

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

40 enrolled

Pancreatic Neoplasms

NCT05267106 2025-12-30

FIGHT-209

Other hematologic neoplasm

83 enrolled 18 charts

CNS

Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Recruiting

32 enrolled

Leukemia, Myeloid, Acute

NCT04463771 2025-12-10

POD1UM-204

Phase 2 Active not recruiting

206 enrolled

Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

27 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 1 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT03822117 2025-11-04

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

111 enrolled 17 charts

Acrocephalosyndactylia

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03914794 2025-10-03

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

30 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06389799 2025-08-28

PERELI

33 enrolled

Sarcoma

Liposarcoma

NCT03656536 2025-08-24

FIGHT-302

Phase 3 Terminated

167 enrolled

Cholangiocarcinoma

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

147 enrolled 22 charts 1 FDA

Acrocephalosyndactylia, Cholangiocarcinoma

NCT05253807 2025-08-05

FIGHT-210

8 enrolled 13 charts

Acrocephalosyndactylia, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06653777 2025-06-05

AcSé PEMI

40 enrolled

Other solid neoplasm

Solid Tumor, Miscellaneous

NCT04294277 2025-04-18

PEGASUS

2 enrolled 6 charts

Carcinoma, Transitional Cell

NCT05565794 2025-04-13

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

2 enrolled

Cholangiocarcinoma

NCT04949191 2024-09-19

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Phase 2 Not yet recruiting

10 enrolled 9 charts

Advanced Malignancies

NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

30 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

NCT06530823 2024-07-31

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Phase 2 Not yet recruiting

38 enrolled

Cholangiocarcinoma

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT04256980 2024-05-30

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

34 enrolled

Cholangiocarcinoma

NCT05529667 2024-05-08

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Phase 1/2 Completed

15 enrolled

Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

NCT04088188 2024-05-06

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Phase 1 Terminated

8 enrolled 14 charts

Cholangiocarcinoma

NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

NCT04096417 2024-02-21

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

14 enrolled 11 charts

Colorectal Neoplasms

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT04591431 2023-10-03

ROME

BreastGastrointestinalThoracic

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT06022289 2023-09-01

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Other solid neoplasm

Solid Tumor

NCT05997459 2023-08-18

A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant

23 enrolled

Locally Advanced Unresectable Gastric Cancer

NCT05216120 2023-07-03

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Phase 2 Withdrawn

Pancreatic Neoplasms

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

30 enrolled

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05651672 2022-12-15

Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

100 enrolled

Gastrointestinal Neoplasms

NCT05559775 2022-09-29

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

Gastrointestinal Neoplasms

NCT05560334 2022-09-29

A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

Breast

Breast Neoplasms

NCT04003623 2022-05-10

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

1 enrolled 2 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT05287386 2022-03-18

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Advanced Non-Small Cell Lung Cancer

NCT05210946 2022-01-27

A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung

NCT05202236 2022-01-21

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy